FibroGen

Prostate cancer ADC acquired from Fortis breaks FibroGen's clinical losing streak
Fierce Biotech
Thu, 04/4/24 - 10:51 am
FibroGen
antibody-drug conjugate
prostate cancer
FG-3246
AstraZeneca finally drops roxadustat US rights after FDA rejection, trial failure
Fierce Pharma
Tue, 02/27/24 - 11:16 am
AstraZeneca
FibroGen
roxadustat
anemia
FibroGen fails again in DMD, continuing rotten run of phase 3 flops
Fierce Biotech
Wed, 08/30/23 - 10:09 am
FibroGen
Duchenne Muscular Dystrophy
clinical trials
pamrevlumab
FibroGen Looks to Regroup After Rocky Q2 Results, Ongoing Challenges
BioSpace
Tue, 08/8/23 - 10:22 am
FibroGen
earnings
FibroGen CEO Resigns Amid Clinical Losing Streak, Layoffs
BioSpace
Wed, 07/26/23 - 09:39 am
FibroGen
Pharma CEOs
layoffs
FibroGen's cost-cutting search spurs 104 layoffs while ImmuneID also restructures
Fierce Biotech
Wed, 07/19/23 - 05:43 pm
FibroGen
layoffs
ImmuneID
clinical trials
FibroGen plans new round of cost cuts after latest study setback
BioPharma Dive
Mon, 06/26/23 - 08:41 pm
FibroGen
IPF
pamvrelumab
clinical trials
FibroGen’s Duchenne drug misses mark in first large trial
BioPharma Dive
Wed, 06/7/23 - 09:29 pm
FibroGen
clinical trials
Duchenne Muscular Dystrophy
pamrevlumab
FibroGen grabs an option to buy cancer drug startup Fortis
BioPharma Dive
Tue, 05/9/23 - 11:29 pm
FibroGen
Fortis Therapeutics
cancer
FOR46
FibroGen’s anemia pill falls short in blood cancer study
BioPharma Dive
Sun, 05/7/23 - 10:18 pm
FibroGen
bone marrow
clinical trials
roxadustat
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Duchenne muscular dystrophy: major trials and events to watch in 2023
Clinical Trials Arena
Thu, 03/16/23 - 09:49 am
DMD
Duchenne Muscular Dystrophy
clinical trials
gene therapy
FDA
Sarepta Therapeutics
SRP-9001
FibroGen
pamrevlumab
Capricor
CAP-1002
Santhera
ReveraGen
vamorolone
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
AstraZeneca partner FibroGen slaps former employees with trade secret theft lawsuit
Fierce Pharma
Mon, 12/5/22 - 10:46 pm
FibroGen
trade secrets
anemia
After high-profile US rejection for roxadustat, Astellas touts its safety in new pooled analysis
Fierce Pharma
Thu, 05/19/22 - 10:32 am
Astellas
roxadustat
FibroGen
ERA
erythropoietin
AstraZeneca, FibroGen can't agree on roxadustat's path forward in chronic kidney disease after FDA rejection
Fierce Pharma
Tue, 05/10/22 - 10:40 am
AstraZeneca
FibroGen
chronic kidney disease
roxadustat
BMS, Novartis, Akebia and more face FDA approval decisions soon, with big sales on the line
Fierce Pharma
Thu, 03/3/22 - 10:33 am
FDA
drug approvals
FibroGen
AstraZeneca
daprodustat
Bristol Myers Squibb
Opdivo
Roche
tiragolumab
Merck
favezelima
bInnovent
Eli Lilly
Akeso Biopharma
Sino Biopharmaceutical
Novartis
Ukoniq
TG Therapeutics
GW Pharmaceuticals
Marinus Pharmaceuticals
The quest for efficacy in pancreatic cancer
EP Vantage
Thu, 11/11/21 - 10:53 am
pancreatic cancer
Novartis
FibroGen
Tyme Technologies
Erytech
Rafeal Pharmaceuticals
AstraZeneca, FibroGen hope to keep their roxadustat dream alive with new FDA meeting
Fierce Pharma
Wed, 11/10/21 - 10:42 am
FibroGen
AstraZeneca
anemia
roxadustat
FDA
GSK pulls off clean sweep of endpoint hits in anemia phase 3, positioning it to leapfrog AstraZeneca
Fierce Biotech
Mon, 11/8/21 - 10:47 am
GSK
chronic kidney disease
cliincal trials
FDA
AstraZeneca
anemia
erythropoietin
FibroGen

Pages